Data / Form D filings / Oricula Therapeutics LLC
Oricula Therapeutics LLC: Form D filings
Oricula Therapeutics LLC, a biotechnology company in Seattle, WA, filed 5 Form D notices with the SEC between 2013 and 2020. The latest, on April 22, 2020, reports an offering of $500,000 with nothing sold yet.
Find out what Oricula Therapeutics LLC does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 474 39TH AVENUE EAST, Seattle, WA, 98112
- Phone
- (206) 322-7526
- Industry
- Biotechnology
- Entity type
- Limited Liability Company
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1590934
The full lists. Form D filings in Washington: 1,095 rows, $54.75, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 22, 2020 | New notice | $500,000 | $0 | $500,000 | 0 | Yet to occur | sec.gov |
| Dec 22, 2017 | New notice | $2,500,000 | $30,000 | $2,470,000 | 1 | Dec 14, 2017 | sec.gov |
| May 15, 2017 | New notice | $400,000 | $25,000 | $375,000 | 1 | May 12, 2017 | sec.gov |
| Jan 21, 2015 | New notice | $450,000 | $45,000 | $405,000 | 1 | Jan 16, 2015 | sec.gov |
| Nov 4, 2013 | New notice | $150,000 | $75,000 | $75,000 | 4 | Oct 15, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Ed Rubel | Director, Promoter | |
| Vince Groppi | Director, Promoter | |
| Malcolm Gleser | Executive Officer, Director, Promoter |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Apr 20, 2020 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Oricula Therapeutics LLC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.